drugset / Trial / NCT01698866

Low Grade Lymphoma

NCT01698866 ↗

Phase 4 Unknown 40 enrolled Central Hospital, Nancy, France
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the seroconversion rate and the cellular immune response after vaccination against hepatitis B virus in patients with lymphoproliferative syndrome like chronic lymphocytic leukemia stade A and follicular lymphoma without of treatment criteria.

Timeline

Start
2012-07
Primary completion
2017-07
Completion
2018-02

Drugs

EvaluationDrugModalityDoseRoute
Subject GenHevac B Pasteur Vaccine 20 ug —